Literature DB >> 22564057

The CD19/CD81 complex physically interacts with CD38 but is not required to induce proliferation in mouse B lymphocytes.

Felipe Vences-Catalán1, Ranjani Rajapaksa, Shoshana Levy, Leopoldo Santos-Argumedo.   

Abstract

In B lymphocytes, the cell surface receptor CD38 is involved in apoptosis of immature B cells, proliferation and differentiation of mature B cells. Although CD38 has been establish as a receptor, its signaling has been only partially characterized. As a result of the lack of signaling motifs in the cytoplasmic domain, CD38 must use a co-receptor to induce signaling within the cell. Accordingly, CD38 has been associated with different receptors such as the T-cell receptor/CD3 complex on T cells, CD16 on natural killer cells and MHC class II molecules on monocytes. The CD19/CD81 complex has been proposed as a co-receptor for CD38 in human B lymphocytes, but little or no characterization has been performed in mice. In this study the contribution of the CD19/CD81 complex in murine CD38 signaling was evaluated. Proliferation assays were performed using CD19(-/-) or CD81(-/-) deficient mice; CFSE-labeled B lymphocytes from wild-type mice and CD19(-/-) , CD81(-/-) and CD38(-/-) deficient mice were stimulated with agonistic antibodies against CD38. Immunoprecipitation and immunofluorescence were also performed to detect protein-protein interactions. Our results indicate that the CD19/CD81 complex interacts with CD38 but this interaction is not required to induce proliferation in mouse B lymphocytes, suggesting that other receptors may contribute to the proliferation induced by CD38 in B lymphocytes.
© 2012 The Authors. Immunology © 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22564057      PMCID: PMC3449246          DOI: 10.1111/j.1365-2567.2012.03602.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  37 in total

Review 1.  Tetraspanins connect several types of Ig proteins: IgM is a novel component of the tetraspanin web on B-lymphoid cells.

Authors:  François Le Naour; Stéphanie Charrin; Valérie Labas; Jean-Pierre Le Caer; Claude Boucheix; Eric Rubinstein
Journal:  Cancer Immunol Immunother       Date:  2004-01-17       Impact factor: 6.968

2.  CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase.

Authors:  D A Tuveson; R H Carter; S P Soltoff; D T Fearon
Journal:  Science       Date:  1993-05-14       Impact factor: 47.728

3.  The CR2/CD19 complex on human B cells contains the src-family kinase Lyn.

Authors:  C J van Noesel; A C Lankester; G M van Schijndel; R A van Lier
Journal:  Int Immunol       Date:  1993-07       Impact factor: 4.823

4.  A B lymphocyte surface molecule mediating activation and protection from apoptosis via calcium channels.

Authors:  L Santos-Argumedo; C Teixeira; G Preece; P A Kirkham; R M Parkhouse
Journal:  J Immunol       Date:  1993-09-15       Impact factor: 5.422

5.  The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex.

Authors:  R H Carter; D A Tuveson; D J Park; S G Rhee; D T Fearon
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

6.  Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells.

Authors:  Silvia Deaglio; Mercedes Zubiaur; Armando Gregorini; Flavia Bottarel; Clara M Ausiello; Umberto Dianzani; Jaime Sancho; Fabio Malavasi
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

7.  CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells.

Authors:  Silvia Deaglio; Andrea Capobianco; Luciana Bergui; Jan Dürig; Fortunato Morabito; Ulrich Dührsen; Fabio Malavasi
Journal:  Blood       Date:  2003-05-22       Impact factor: 22.113

8.  CD38 is associated with lipid rafts and upon receptor stimulation leads to Akt/protein kinase B and Erk activation in the absence of the CD3-zeta immune receptor tyrosine-based activation motifs.

Authors:  Mercedes Zubiaur; Olga Fernández; Enza Ferrero; Javier Salmerón; Bernard Malissen; Fabio Malavasi; Jaime Sancho
Journal:  J Biol Chem       Date:  2001-10-31       Impact factor: 5.157

9.  A role for lipid rafts in B cell antigen receptor signaling and antigen targeting.

Authors:  P C Cheng; M L Dykstra; R N Mitchell; S K Pierce
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

10.  Ontogeny, distribution and function of CD38-expressing B lymphocytes in mice.

Authors:  F R Donís-Hernández; R M Parkhouse; L Santos-Argumedo
Journal:  Eur J Immunol       Date:  2001-04       Impact factor: 5.532

View more
  5 in total

1.  CD38, CD81 and BAFFR combined expression by transitional B cells distinguishes active from inactive systemic lupus erythematosus.

Authors:  Ana Henriques; Isabel Silva; Luís Inês; M Margarida Souto-Carneiro; M Luísa Pais; Hélder Trindade; José António Pereira da Silva; Artur Paiva
Journal:  Clin Exp Med       Date:  2015-04-18       Impact factor: 3.984

Review 2.  B cell MHC class II signaling: A story of life and death.

Authors:  Divya Sai Katikaneni; Lei Jin
Journal:  Hum Immunol       Date:  2018-04-30       Impact factor: 2.850

3.  Dysregulation of Signaling Pathways Due to Differentially Expressed Genes From the B-Cell Transcriptomes of Systemic Lupus Erythematosus Patients - A Bioinformatics Approach.

Authors:  S Udhaya Kumar; D Thirumal Kumar; R Siva; C George Priya Doss; Salma Younes; Nadin Younes; Mariem Sidenna; Hatem Zayed
Journal:  Front Bioeng Biotechnol       Date:  2020-04-30

4.  Identification of Integrin β1 as a Novel PAG1-Interacting Protein Involved in the Inherent Radioresistance of Human Laryngeal Carcinoma.

Authors:  Xiaoxia Dong; Zhiguo Luo; Tiantian Liu; Jingjing Chai; Qing Ke; Li Shen
Journal:  J Cancer       Date:  2018-10-18       Impact factor: 4.207

5.  CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.

Authors:  Kemeng Wang; Guoqing Wei; Delong Liu
Journal:  Exp Hematol Oncol       Date:  2012-11-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.